National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
714-X (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 06/12/2009



Purpose of This PDQ Summary






Overview






General Information






History






Laboratory/Animal/Preclinical Studies






Human/Clinical Studies






Adverse Effects







Overall Level of Evidence for 714-X






Changes to This Summary (06/12/2009)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Overall Level of Evidence for 714-X

To assist readers in evaluating the results of human/clinical studies of complementary and alternative medicine (CAM) treatments for cancer, a scoring system has been devised that allows studies of individual treatments to be ranked according to the strength of their evidence (i.e., their level of evidence). Not all studies, however, are given a level of evidence score. To be eligible, a study must:

  • Evaluate a therapeutic outcome(s), such as tumor response, improvement in survival, or carefully measured improvement in quality of life.
  • Be reported in a peer-reviewed scientific journal.
  • Have its clinical findings published in sufficient detail that a meaningful evaluation can be made.

Evidence from studies that do not meet these requirements is considered extremely weak. In addition to scoring individual studies, an overall level of evidence assessment is usually made.

Because no study of the use of 714-X in humans has been reported in a peer-reviewed scientific journal, no level of evidence analysis is possible for this treatment. Therefore, at this time, the use of 714-X as a treatment for cancer cannot be recommended outside the context of well-designed clinical trials.

For additional information about levels of evidence analysis, refer to Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov